Spatial Biology Market Report - Second Edition: 2024

This report provides an overview of the spatial biology market from 2024 to 2029. The spatial biology market, as defined in this report, is comprised of revenue from instruments and reagents sold to academic, biopharma, and CRO customers, along with service revenues generated by CROs and reference labs. This market is moderately consolidated today, with the top vendors including 10x Genomics, NanoString, Akoya Biosciences,and Bio-Techne making up ~60% of the market, however, multiple other mid-sized and smaller-sized players (e.g., Standard BioTools, Leica Microsystems, Ultivue, and Vizgen) are poised to capture share as the market grows and evolves.

For this report, we leverage a combination of secondary research (e.g., analysis of quarterly and annual reports, earnings call transcripts, clinical trials, congress abstracts, company websites, etc.) and primary research (e.g., 26 interviews with key spatial biology stakeholders from academia, biopharma, and leading specialty CROs; 64 survey respondents across academia, biopharma, and leading specialty CROs) to assess the current and expected future adoption and utilization of spatial biology tools and technologies, and to characterize the key market dynamics. From our research and analysis, we estimate that the spatial biology market is expected to reach ~$860M in 2024 and is expected to grow 21% p.a. in the next 5 years, to reach ~$2.27B by 2029.* Our analysis indicates continued market growth within academia and rapid expansion in use by biopharma and CROs, particularly for use within clinical trials.

For each of the subsegments analyzed, we present forecasted data from 2024-2029. In addition, we detail market drivers (e.g., increased access and familiarity) and moderators (e.g., high cost of instruments and reagents), market trends (acceleration in the adoption of spatial transcriptomics), a high-level customer breakdown (academia, large pharma, small pharma, CROs), and offer key information on top competitors. All analyses are based on publicly reported data and DeciBio research and analysis.**

*We do believe that uncertainty to these forecasts exist (potential range: 20-45% p.a.), considering that the field is relatively young and pivotal developments may occur within the forecasted period that could determine future adoption of the technology; ** Disclaimer: Some of the companies listed in this report may be DeciBio Consulting clients and customers

‍

Drivers

1. ‍Increased Access and Familiarity: Stakeholders, notably pharma, can scale up via CROs; An increasing number of companies have enough data to justify further investment‍
2. Improving Workflows: Integrated end-to-end workflows enable higher throughput, critical for scaling up and improving reproducibility‍
3. Integration of AI and Digital Pathology: AI enables more advanced spatial analysis; pharma invests heavily in informatics and spatial vendors continue to partner with DP companies‍
4. Plex and Resolution Advances: Single-cell resolution at a high plex and large ROI enables new levels of data, building on traditional single cell analysis

‍

Moderators

1. Cost: CapEx, reagent, and analysis costs are high and unlikely to drop in the near-term, limiting use in high-volume studies
2. Reproducible Data: Reproducibility across instruments, kits, and users remains a challenge; many factors can add variability, further complicating analysis
3. Unclear Biological and Clinical Significance: Data showing clear clinical utility that can’t be replicated by less expensive methods (e.g., IHC) is still needed to justify scaling up spend
4. Tissue Access: Access to tissue that has been handled and stored properly is challenging; many diseases lack routine biopsies and large tissue banks for research  
   

Report Scope

Technologies and Revenues Included:

• Spatial Biology - the study of biology and pathophysiology in which the spatial context of the analytes is taken into consideration (including both single-and multiplex spatial analyses)
• Technology classes which are designed to profile and analyze multiplex biomarkers in situ including includes mIF, mIHC, digital-spatial profiling, multiplex FISH, and imaging mass cytometry
• Instrument and reagent revenues associated with the purchase of spatial biology platforms or reagents / kits used to run the assays, as well as service revenues associated with wet-lab processing of spatial slides or image analysis (e.g., by CROs / Reference Labs) ‍
• Sales of products and services to academic, biotech / pharmaceutical companies, and CRO customers including both therapeutic companies and diagnostic / analytical tools companies

‍

Technologies and Revenues Excluded:

• Digital pathology / image analysis in which automated image analysis, algorithms, or pathologist-supported software is used to perform whole slide image analysis of any sort
• Service revenue related to CDx development‍
• Histology testing without spatial analyses including multiplex assays which analyze presence or intensity of analytes only

‍

Segmentations Covered in Market Analysis:

‍

Customer:

• Academia
• Large Biopharma
• Small Biopharma
• CRO / Reference Labs

Products / Services:

• Instruments
• Reagents
• Services
• Image Analysis Services

Technology:

• Proteomics - mIHC
• Proteomics - mIF
• Spatial Transcriptomics
• Other

Plex Level:

• 2-3 Plex
• 4-8 Plex
• 9-20 Plex
• 20+ Plex

Analyte:

• Protein
• RNA
• Other

Application:

• Basic / Discovery Research
• Translational / Clinical Research
• Routine Clinical Diagnostic

Therapeutic Area:

• Oncology
• Immuno-oncology
• Neuroscience
• Infectious Disease
• Cardiology
• Other

Competitors (grouped into tiers):

• 10x Genomics
• Advanced Cell Diagnostics
• Akoya Biosciences
• Ionpath
• Leica Microsystems
• NanoString
• NeoGenomics
• Standard Biotools
• Ultivue
• Vizgen
• Other

Geography:

• United States
• Europe
• Rest of World

Companies Profiled:

• 10x Genomics
• Advanced Cell Diagnostics
• Akoya Biosciences
• Leica
• Lunaphore
• NanoString
• NeoGenomics
• Standard BioTools
• Ultivue
• Vizgen